Fused Tricyclic Kinase Inhibitors for Multi-Kinase Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for targeting kinases to modulate autophagy and treat diseases such as cancer and pulmonary fibrosis are limited, particularly in addressing the aberrant activation of kinases like ULK1, FAK, ALK, CDK7, HPK1, AXL, FLT3, and TNK1.
Innovation Solution
Development of a novel class of kinase inhibitors represented by Formula (I) and its derivatives, which target specific kinases to regulate autophagy and inhibit kinase activity, including ULK, FAK, ALK, CDK7, HPK1, AXL, FLT3, and TNK1, for treating various cancers and immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing kinase inhibitors are used to target specific kinases, then kinase activity can be inhibited, but the therapeutic coverage for multiple diseases and kinases is limited
Solution Approach 1:
The patent applies universality by designing a single fused tricyclic compound scaffold (Formula I) that can inhibit multiple different kinases (ULK1, FAK, ALK, CDK7, HPK1, AXL, FLT3, TNK1) and treat multiple diseases simultaneously. The core structure serves multiple functions by binding to different kinase targets, eliminating the need for separate inhibitors for each kinase and disease indication.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying substituent groups (R1-R6, X, Y, Z) at different positions of the fused tricyclic core structure to optimize binding affinity and selectivity for specific kinases. By changing chemical parameters such as substituent types, positions, and configurations, the same scaffold can be adapted to target different kinases with high specificity.
2Reliability
If multiple separate kinase inhibitors are developed for different kinases, then specific kinase activity can be targeted, but the number of compounds and development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor space into a core fused tricyclic scaffold (Formula I) and variable substituent groups. This segmentation allows the core structure to provide the fundamental kinase-inhibiting activity while substituent groups can be independently optimized for specific kinase targets, reducing the need to develop entirely new compounds for each kinase.
Solution Approach 2:
The patent merges multiple kinase inhibitor functions into a single compound class. Instead of developing separate inhibitors for ULK1, FAK, ALK, CDK7, HPK1, AXL, FLT3, and TNK1, the fused tricyclic scaffold combines the ability to inhibit all these kinases within one structural framework, thereby reducing the total number of compounds needed.
3Adaptability or versatility
If broad-spectrum kinase inhibitors are designed to cover multiple kinases, then therapeutic versatility improves, but selectivity and specificity for individual kinases may be compromised
Solution Approach 1:
The patent applies local quality by creating different regions within the fused tricyclic scaffold that interact with specific kinase targets. Different substituent groups (R1-R6, X, Y, Z) are positioned at specific locations to provide localized interactions with particular kinase residues, enabling selective binding to individual kinases while maintaining overall multi-kinase coverage through appropriate substituent selection.
Data Source
AI summary
Provided in the present ivention is a class of compounds containing a fused tricyclic structure Specifically, provided in the present invention is a compound having a structure as shown in formula (I), or anoptical isomer, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative, a hydrate or a solvate thereofThe compound can effectively inhibit protein kinase (including ULK, FAK, ALK, CDK7, HPKI, AXL, FLT3TNK1, etc.), and is used for treating or preventing diseases or conditionSRelated to the activity or expression levelof kinase.